Beam Therapeutics Appoints Sravan Emany as New CFO, Shares Up [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
He will assume his new role on Dec. 19, 2024. Emany most recently served as CFO and the chief operating officer at Ironwood Pharmaceuticals. He previously held senior leadership positions at Integra LifeSciences Holdings Corporation, a healthcare company, and also worked as an investment banker at Bank of America and BofA Securities. Emany also held other financial roles at Goldman Sachs and Morgan Stanley and served on the board of directors of Assertio Holdings. BEAM's erstwhile CFO, Terry-Ann Burrell, stepped down from her role effective Aug. 9, 2024. Year to date, shares of Beam Therapeutics have decreased 1.8% compared with the industry's decline of 7.5%. Image Source: Zacks Investment Research BEAM's pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Beam Therapeutics is develo
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Cantor Fitzgerald to a "hold" rating.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
BEAM
Earnings
- 11/5/24 - Miss
BEAM
Sec Filings
- 12/19/24 - Form 4
- 12/19/24 - Form 3
- 12/9/24 - Form 8-K
- BEAM's page on the SEC website